https://www.selleckchem.com/pr....oducts/sulfatinib.ht
Aim To investigate the efficacy of adjuvant chemotherapy plus tumor-infiltrating lymphocytes (TILs) therapy in osteosarcoma patients with a poor response to neoadjuvant chemotherapy. Materials methods 40 patients received adjuvant chemotherapy (Group 1) and 40 patients received adjuvant chemotherapy plus TILs therapy (Group 2). Disease-free survival (DFS) and overall survival (OS) were analyzed by Kaplan-Meier analysis. Results The median DFS (mDFS; 65.3 months) and median OS (mOS; 95.8 months) in Group 2 were significantly pro
Kao
Komentar
Udio
